{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:27:34Z","timestamp":1792056454497,"version":"4.4.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although venous thromboembolism (VTE) is an important treatment and disease-related complication in myeloma, a validated risk prediction model including disease-specific variables such as cytogenetics or tumor burden is lacking. The aim of this study was to develop a new risk prediction model for VTE in the context of modern antimyeloma therapy. All consecutive patients diagnosed at the Cleveland Clinic between 2008 and 2018 and with available data on baseline candidate risk factors constituted the derivation cohort. The primary outcome was VTE (deep venous thrombosis\/pulmonary embolism) within 1 year of treatment initiation. A multivariable model was used, and weights were derived from subdistribution hazard ratios to construct a risk score. The model was validated both by internal bootstrap validation and in an external validation cohort. The derivation cohort consisted of 783 patients. A 5-component risk prediction tool, named the PRISM score, was developed, including the following variables: prior VTE, prior surgery, immunomodulatory drug use, abnormal metaphase cytogenetics, and Black race. The c-statistic of the model was 0.622 (95% confidence interval [CI], 0.567-0.674). The model stratified patients into low, intermediate, and high risk, with 12-month cumulative VTE incidence of 2.7%, 10.8%, and 36.5%, respectively. Risk of VTE increased significantly with increasing score in both the derivation and the external validation data sets,\u00a0with a subdistribution hazard ratio per 1-point increase of 1.28 (95% CI, 1.19-1.39; P\u00a0&amp;lt; .001) and 1.23 (95% CI, 1.07-1.41; P\u00a0= .004) respectively. Although the PRISM score can guide clinicians in identifying patients at a high risk of VTE, additional external validation is necessary for incorporation into routine clinical practice.<\/jats:p>","DOI":"10.1182\/blood.2022015727","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T19:01:43Z","timestamp":1656615703000},"page":"2443-2450","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"first","affiliation":[{"name":"1Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rybicki","sequence":"additional","affiliation":[{"name":"2Taussig Cancer Center, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0960-7269","authenticated-orcid":false,"given":"Wei","family":"Wei","sequence":"additional","affiliation":[{"name":"2Taussig Cancer Center, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Valent","sequence":"additional","affiliation":[{"name":"2Taussig Cancer Center, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8153-0438","authenticated-orcid":false,"given":"Beth M.","family":"Faiman","sequence":"additional","affiliation":[{"name":"2Taussig Cancer Center, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy J.","family":"Samaras","sequence":"additional","affiliation":[{"name":"2Taussig Cancer Center, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[{"name":"2Taussig Cancer Center, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[{"name":"2Taussig Cancer Center, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2022120816274192200_bib1","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"issue":"24","key":"2022120816274192200_bib2","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2022120816274192200_bib3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ajh.25764","article-title":"Treatment and disease-related complications in multiple myeloma: implications for survivorship","volume":"95","author":"Chakraborty","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"2022120816274192200_bib4","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood"},{"issue":"25","key":"2022120816274192200_bib5","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJM200106213442516","article-title":"Deep venous thrombosis and thalidomide therapy for multiple myeloma","volume":"344","author":"Osman","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2022120816274192200_bib6","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4065\/80.12.1549","article-title":"Thalidomide therapy and deep venous thrombosis in multiple myeloma","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"2022120816274192200_bib7","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/cncr.23336","article-title":"Thromboembolic events with lenalidomide-based therapy for multiple myeloma","volume":"112","author":"Menon","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"2022120816274192200_bib8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"2022120816274192200_bib9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"2022120816274192200_bib10","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.6004\/jnccn.2018.0084","article-title":"NCCN Guidelines Insights: cancer-associated venous thromboembolic disease, version 2.2018","volume":"16","author":"Streiff","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"7","key":"2022120816274192200_bib11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"9","key":"2022120816274192200_bib12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials [published correction appears in Blood. 2020;136(17):1994]","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2022120816274192200_bib13","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/cncr.32682","article-title":"Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis","volume":"126","author":"Chakraborty","year":"2020","journal-title":"Cancer"},{"issue":"4","key":"2022120816274192200_bib14","first-page":"844","article-title":"MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs","volume":"110","author":"Leleu","year":"2013","journal-title":"Thromb Haemost"},{"issue":"11","key":"2022120816274192200_bib15","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2022120816274192200_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"2022120816274192200_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10","key":"2022120816274192200_bib18","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/bloodadvances.2019001275","article-title":"Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma","volume":"4","author":"Mellors","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2022120816274192200_bib19","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/sj.leu.2404330","article-title":"The role of cytogenetics in myeloma","volume":"20","author":"Zhan","year":"2006","journal-title":"Leukemia"},{"issue":"10","key":"2022120816274192200_bib20","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"issue":"5","key":"2022120816274192200_bib21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.bmt.1701943","article-title":"Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma","volume":"24","author":"Rajkumar","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2022120816274192200_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","article-title":"Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation","volume":"126","author":"Zangari","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"2022120816274192200_bib23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1160\/TH13-12-1020","article-title":"Implications of cytogenetics for venous thromboembolism in acute myeloid leukaemia","volume":"113","author":"Lee","year":"2015","journal-title":"Thromb Haemost"},{"issue":"3","key":"2022120816274192200_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clml.2020.11.015","article-title":"Thromboembolism incidence and risk factors in multiple myeloma after first exposure to immunomodulatory drug-based regimens","volume":"21","author":"Patel","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2022120816274192200_bib25","first-page":"446","article-title":"Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures","volume":"90","author":"White","year":"2003","journal-title":"Thromb Haemost"},{"issue":"3","key":"2022120816274192200_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/2151458516658330","article-title":"Patients with multiple myeloma have more complications after surgical treatment of hip fracture","volume":"7","author":"Park","year":"2016","journal-title":"Geriatr Orthop Surg Rehabil"},{"issue":"14","key":"2022120816274192200_bib27","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1161\/CIRCULATIONAHA.113.006472","article-title":"Racial and regional differences in venous thromboembolism in the United States in 3 cohorts","volume":"129","author":"Zakai","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"2022120816274192200_bib28","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"2022120816274192200_bib29","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/rth2.12411","article-title":"Venous thromboembolism in multiple myeloma is associated with increased mortality","volume":"4","author":"Schoen","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"2022120816274192200_bib30","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1525-1497.2000.06419.x","article-title":"Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life","volume":"15","author":"Kahn","year":"2000","journal-title":"J\u00a0Gen Intern Med"},{"issue":"5","key":"2022120816274192200_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/MOH.0b013e3283063a51","article-title":"Long-term outcome of pulmonary embolism","volume":"15","author":"Meyer","year":"2008","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"2022120816274192200_bib32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"2022120816274192200_bib33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.16653","article-title":"Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents","volume":"190","author":"Cornell","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2022120816274192200_bib34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ajh.25459","article-title":"Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study","volume":"94","author":"Pegourie","year":"2019","journal-title":"Am J Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/23\/2443\/2019782\/blood_bld-2022-015727-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/23\/2443\/2019782\/blood_bld-2022-015727-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T16:28:04Z","timestamp":1670516884000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/23\/2443\/485748\/Abnormal-metaphase-cytogenetics-predicts-venous"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":34,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022015727","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]}}}